Longevity Tech Fund

Longevity Tech Fund

Longevity Tech Fund was established in South Florida as a sector-specialist vehicle dedicated to the emerging longevity economy. The firm concentrates on Seed and early-stage venture deals, looking for companies developing biological age diagnostics, senolytic therapies, and AI-enabled drug discovery for age-related diseases. Its mandate reflects the growing convergence of computational biology and preventative medicine. The firm's investment strategy bridges pure-play biotech and digital health, spanning therapeutic platforms, consumer diagnostics, and machine-learning tools for clinical longevity. Its geographic focus is primarily North America, though it reviews opportunities in European and Israeli longevity hubs. Rather than broad fund commitments, Longevity Tech Fund typically writes direct checks into early equity rounds, sometimes alongside top-tier biotech syndicates. The firm operates without public disclosure of AUM or headcount, keeping a low profile typical of new-wave science-focused venture platforms. It maintains no listed satellite offices beyond its Boca Raton headquarters. In recent years, capital has increasingly flowed into longevity biotechnology, with global investment in the sector topping $6 billion in 2022, creating a favorable environment for specialized early-stage managers (per Nature Biotechnology, 2023). Longevity Tech Fund's structural posture is that of a thematic early-stage investor rather than a general family-office co-investor or institutional fund-of-funds. Its singular thesis — investing in the science of lifespan extension at the earliest stages — places it in a narrow cohort of dedicated longevity-first managers, distinct from larger healthtech funds that treat aging as one slice of a diversified mandate.